A wide interindividual variability of urinary 6β-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition

Therapeutic Drug Monitoring

Volumn 24, Issue 6, 2002, Pages 722-727

  Inagaki, Kazuhiro ^a   Inagaki, Masami ^a   Kataoka, Tomomi ^a   Sekido, Izumi ^a   Gill, Mark A ^b   Nishida, Mikio ^a  

^a MEIJO UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

6 hydroxycortisol; Cortisol; CYP3A; Genetic polymorphism; Japanese

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A; FLUDROCORTISONE; HYDROCORTISONE; 6 BETA-HYDROXYCORTISOL; CREATININE; DRUG DERIVATIVE;

ADULT; ARTICLE; CORRELATION ANALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; ADOLESCENT; CLINICAL TRIAL; JAPAN; REFERENCE VALUE; REGRESSION ANALYSIS; SEXUAL DEVELOPMENT; URINE;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; FEMALE; HUMANS; HYDROCORTISONE; JAPAN; MALE; REFERENCE VALUES; REGRESSION ANALYSIS; SEX CHARACTERISTICS;

EID: 0036890995     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200212000-00007     Document Type: Article

References (29)

1. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990;45:1-38.
2. Kleinbloesem CH, Vanbrummelen P, Farber H, et al. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 1984;33:3721-4.
3. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1998:37:2507-10.
4. Horsmans Y, Desager JP, Harvengt C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992;71:249-61.
5. Sata F, Sapone A, Elizonda G, et al. CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharm Ther 2000;67: 48-56.
6. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001;11:447-58.
7. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-31.
8. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
9. Ged C, Rouillon MJ, Pichard L, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28: 373-87.
10. Lykkesfeldt J, Loft S, Poulsen HE. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Sci Appl 1994;660:23-9.
11. Ono T, Tanida K, Shibata H, et al. High-performance liquid chromatographic determination of 6 beta-hydroxycortisol in urine. Chem Pharm Bull 1986;34:2522-7.
12. Bonsnes RW, Taussky HA. On the colorimetric determination of creatinine by the Jaffe reaction. J Biol Chem 1945;158:581-91.
13. Endrenyi L, Patel M. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: The NTV plot. Br J Clin Pharmacol 1991;32:159-66.
14. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001;69:333-9.
15. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001;11:781-91.
16. Watkins PB, Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
17. Thrasher K, Werk EE, Choi LJ, et al. The measurement, excretion and source of urinary 6-hydroxycortisol in humans, Steroids 1969;14:455-68.
18. Pal SB. 6-Hydroxylation of cortisol and urinary 6β-hydroxycortisol. Metabolism 1978;27:1003-11.
19. Kinirons MT, O'Shea D, Kim RB. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999;66:224-31.
20. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989;264:10388-95.
21. Wrighton SA, Ring BJ, Watkins PB, et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:97-105.
22. Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000;10:415-24.
23. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
24. Nakamura T, Sato Y, Murayama N, et al. Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individual. Biol Pharm Bull 2001;24:954-7.
25. Watkins PB, Muray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid inducible liver cytochromes P-450, J Clin Invest 1989;83:688-97.
26. Watkins PB, Hamilton TA, Anesley TM, et al. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
27. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokin Biopharm 1996;24:475-90.
28. Krecic-Shepard ME, Park K., Barnas C, et al. Race and sex influence clearance of nifedipine: Results of a population study. Clin Pharmacol Ther 2000:68:130-42.
29. Lin Y, Anderson GD. Kantor E, et al. Differences in the urinary excretion of 6β-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol 1999;39:578-82.